Qinghai Spring Medicinal Resources Technology Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Xuefeng Zhang

Chief Executive Officer (CEO)

CN¥625.6k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	9.5yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	4.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Xuefeng Zhang (54 yo)

9.5yrs

Permanencia

CN¥625,600

Compensación

Mr. Xuefeng Zhang serves as Chairman & GM of Qinghai Spring Medicinal Resources Technology Co., Ltd. since May 15, 2015.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Xuefeng Zhang	Chairman & GM	9.5yrs	CN¥625.60k	sin datos
Xuemin Gao	Independent Director	4.4yrs	CN¥60.00k	sin datos
Jin Zhang	Supervisor	2.5yrs	sin datos	sin datos

4.4yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de 600381 se considera experimentada (4.4 años de antigüedad promedio).

Qinghai Spring Medicinal Resources Technology Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Qinghai Spring Medicinal Resources Technology Co., Ltd., Annual General Meeting, Jun 21, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.053 loss per share (vs CN¥0.034 loss in 3Q 2023)

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.056 loss per share (vs CN¥0.037 loss in 2Q 2023)

New major risk - Share price stability

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2024 Results on Aug 02, 2024

Qinghai Spring Medicinal Resources Technology Co., Ltd., Annual General Meeting, Jun 21, 2024

New minor risk - Share price stability

First quarter 2024 earnings released: CN¥0.046 loss per share (vs CN¥0.049 loss in 1Q 2023)

Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) announces an Equity Buyback for CNY 50 million worth of its shares.

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released: CN¥0.034 loss per share (vs CN¥0.045 loss in 3Q 2022)

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: CN¥0.037 loss per share (vs CN¥0.043 loss in 2Q 2022)

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023

First quarter 2023 earnings released: CN¥0.049 loss per share (vs CN¥0.04 loss in 1Q 2022)

Third quarter 2022 earnings released: CN¥0.045 loss per share (vs CN¥0.017 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.043 loss per share (vs CN¥0.07 loss in 2Q 2021)

Full year 2021 earnings released: CN¥0.42 loss per share (vs CN¥0.54 loss in FY 2020)

Third quarter 2021 earnings released: CN¥0.017 loss per share (vs CN¥0.066 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.07 loss per share (vs CN¥0.08 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.54 loss per share (vs CN¥0.01 profit in FY 2019)

New 90-day high: CN¥7.12

New 90-day high: CN¥6.86

New 90-day high: CN¥6.24

Hongta Hotland Asset Management Co., Ltd. completed the acquisition of 5.62% stake in Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) from Tibet Rongen Technology Co., Ltd.

Third quarter earnings released

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2020 Results on Oct 22, 2020

First half earnings released

New 90-day high - CN¥6.00

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2020 Results on Aug 31, 2020

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad